Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Durasphere FI is an injectable bulking agent developed by Carbon Medical Technologies for the treatment of fecal incontinence. It consists of non-migratory, pyrolytic carbon-coated zirconium oxide beads suspended in a water-based carrier gel. The beads, which range in size from 212 to 500 microns, are designed to provide permanent mechanical bulk to the anal canal, thereby enhancing the closure of the anal sphincter and reducing incontinent episodes. Unlike collagen-based bulking agents, Durasphere is non-biodegradable and does not require skin testing. While the product is FDA-approved for stress urinary incontinence under the name Durasphere EXP, clinical development for fecal incontinence (Durasphere FI) was explored in trials such as NCT00762047, which was terminated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Durasphere FI.